Top

Published in:

01-01-2013

Role of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Pathologic Response to Preoperative Chemoradiation Therapy in Patients With Resectable T3 Pancreatic Cancer

Authors: Hirotada Kittaka, Hidenori Takahashi, Hiroaki Ohigashi, Kunihito Gotoh, Terumasa Yamada, Yasuhiko Tomita, Yoshihisa Hasegawa, Masahiko Yano, Osamu Ishikawa

Published in: World Journal of Surgery | Issue 1/2013

Abstract

Background

The purpose of this study was to evaluate whether ¹⁸F-fluorodeoxyglucose positron emission tomography in combination with computed tomography (FDG-PET/CT) could correctly predict the pathologic response to preoperative chemoradiation therapy (CRT) for resectable pancreatic cancer.

Methods

Each of the 40 patients underwent FDG-PET/CT before and after preoperative CRT. The maximum standard uptake value (SUV) was measured for the primary tumor before and after preoperative CRT, defined as pre-CRT SUV and post-CRT SUV, respectively. The proportional alteration of the SUV decline (regression index) between post-CRT SUV and pre-CRT SUV was also calculated. These three indicators were associated with the pathologic response.

Results

Patients were classified as 21 responders and 19 nonresponders according to the histologic features. A pre-CRT SUV ≥4.7 was seen in 15 (71 %) of 21 responders and in 6 (32 %) of 19 nonresponders (p = 0.03). A regression index ≥0.46 was seen in 15 (71 %) responders and 5 (26 %) nonresponders (p = 0.01).

Conclusions

A better pathological response can be expected for pancreatic cancer patients who have a high regression index (≥0.46) and a high pre-CRT SUV (≥4.7). The SUV measurement using FDG-PET/CT is a useful tool for predicting the pathologic response to preoperative CRT.

Cameron JL, Crist DW, Sitzmann JV et al (1991) Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161:120–124 discussion 124–125PubMedCrossRef

Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma: clinicopathologic analysis of 5-year survivors. Ann Surg 223:273–279PubMedCrossRef

Willett CG, Lewandrowski K, Warshaw AL et al (1993) Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy. Ann Surg 217:144–148PubMedCrossRef

Staley CA, Lee JE, Cleary KR et al (1996) Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171:118–124 discussion 124–115PubMedCrossRef

Breslin TM, Hess KR, Harbison DB et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123–132PubMedCrossRef

Kamthan AG, Morris JC, Dalton J et al (1997) Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 15:2920–2927PubMed

Mehta VK, Fisher G, Ford JA et al (2001) Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 5:27–35PubMedCrossRef

Pendurthi TK, Hoffman JP, Ross E et al (1998) Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma. Am Surg 64:686–692PubMed

Snady H, Bruckner H, Cooperman A et al (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma: an outcomes trial. Cancer 89:314–327PubMedCrossRef

10.

Talamonti MS, Small W Jr, Mulcahy MF et al (2006) A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150–158PubMedCrossRef

11.

Chun YS, Cooper HS, Cohen SJ et al (2011) Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 18:3601–3607PubMedCrossRef

12.

White RR, Xie HB, Gottfried MR et al (2005) Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 12:214–221PubMedCrossRef

13.

Delbeke D, Martin WH (2001) Positron emission tomography imaging in oncology. Radiol Clin North Am 39:883–917PubMedCrossRef

14.

Hustinx R, Benard F, Alavi A (2002) Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32:35–46PubMedCrossRef

15.

Kubota K (2001) From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 15:471–486PubMedCrossRef

16.

Okamoto K, Koyama I, Miyazawa M et al (2011) Preoperative [¹⁸F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol 16:39–44PubMedCrossRef

17.

Hopkins S, Fakih M, Yang GY (2010) Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation. World J Gastrointest Oncol 2:213–217PubMedCrossRef

18.

Kwee RM (2010) Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of ¹⁸F FDG PET: a systematic review. Radiology 254:707–717PubMedCrossRef

19.

Choi M, Heilbrun LK, Venkatramanamoorthy R et al (2010) Using ¹⁸F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol 33:257–261PubMed

20.

Sobin L, Gospodarowicz M, Wittekind C (eds) (2010) TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell, New York

21.

Ohigashi H, Ishikawa O, Eguchi H et al (2009) Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 250:88–95PubMedCrossRef

22.

Evans DB, Rich TA, Byrd DR et al (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335–1339PubMedCrossRef

23.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

24.

Brucher BL, Weber W, Bauer M et al (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233:300–309PubMedCrossRef

25.

Flamen P, Van Cutsem E, Lerut A et al (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13:361–368PubMedCrossRef

26.

Wieder HA, Brucher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900–908PubMedCrossRef

27.

Van Heijl M, Omloo JM, van Berge Henegouwen MI et al (2011) Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 253:56–63PubMedCrossRef

28.

Cascini GL, Avallone A, Delrio P et al (2006) ¹⁸F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 47:1241–1248PubMed

29.

Capirci C, Rampin L, Erba PA et al (2007) Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 34:1583–1593PubMedCrossRef

30.

Hur H, Kim NK, Yun M et al (2011) ¹⁸Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. J Surg Oncol 103:17–24PubMedCrossRef

31.

Hawkins DS, Schuetze SM, Butrynski JE et al (2005) [¹⁸F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828–8834PubMedCrossRef

32.

Evilevitch V, Weber WA, Tap WD et al (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14:715–720PubMedCrossRef

33.

Benz MR, Czernin J, Tap WD, et al (2010) FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma 143540. Epub Apr 18

34.

Cerfolio RJ, Bryant AS, Winokur TS et al (2004) Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 78:1903–1909 discussion 1909PubMedCrossRef

35.

Shiraishi K, Nomori H, Ohba Y et al (2010) Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography. Ann Thorac Cardiovasc Surg 16:394–400PubMed

36.

Schellenberg D, Quon A, Minn AY et al (2010) ¹⁸Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 77:1420–1425PubMedCrossRef

37.

Nakata B, Chung YS, Nishimura S et al (1997) ¹⁸F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79:695–699PubMedCrossRef

38.

Nakata B, Nishimura S, Ishikawa T et al (2001) Prognostic predictive value of ¹⁸F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 19:53–58PubMed

39.

Heinrich S, Schafer M, Weber A et al (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248:1014–1022PubMedCrossRef

40.

Smith IC, Welch AE, Hutcheon AW et al (2000) Positron emission tomography using [(¹⁸)F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676–1688PubMed

41.

Katz MH, Fleming JB, Bhosale P, et al (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer doi: 10.1002/cncr.27636. [Epub ahead of print]

42.

Morgan DE, Waggoner CN, Canon CL et al (2010) Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT. AJR Am J Roentgenol 194:615–622PubMedCrossRef

43.

Takahashi H, Ohigashi H, Ishikawa O et al (2012) Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg 255:95–102PubMedCrossRef

Title: Role of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Pathologic Response to Preoperative Chemoradiation Therapy in Patients With Resectable T3 Pancreatic Cancer
Authors: Hirotada Kittaka
Hidenori Takahashi
Hiroaki Ohigashi
Kunihito Gotoh
Terumasa Yamada
Yasuhiko Tomita
Yoshihisa Hasegawa
Masahiko Yano
Osamu Ishikawa
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 1/2013
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-012-1775-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Pathologic Response to Preoperative Chemoradiation Therapy in Patients With Resectable T3 Pancreatic Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value

Therapeutic Mammaplasty for Breast Cancer: Oncological and Aesthetic Outcomes

Risk Factors of Hypoparathyroidism Following Total Thyroidectomy for Thyroid Cancer

Use of a Transanal Drainage Tube for Prevention of Anastomotic Leakage and Bleeding after Anterior Resection for Rectal Cancer

Measuring Global Surgical Disparities: A Survey of Surgical and Anesthesia Infrastructure in Bangladesh

Predicting Hollow Viscus Injury in Blunt Abdominal Trauma with Computed Tomography